Dual Inhibitors: RAAS Blockers/Combination Therapies: What Do All These Trials Mean?
Publisher
Springer New York
Reference53 articles.
1. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep. 2000;2:402–11.
2. Friedrich S, Schmieder RE. Review of direct renin inhibition by aliskiren. J Renin Angiotensin Aldo Syst. 2013;14:193–6.
3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
5. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int (Suppl). 1994;45:S150–5.